I-Mab Inc. (中国)

The Company and its subsidiaries are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China (the “PRC”) and other countries and regions.
It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The Company s product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for immuno-oncology; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases.
The Company has only one reportable segment.
HISTORY
2014 The Company commenced its operations in November 2014, when its predecessor Third Venture Biopharma (Nanjing) Co., Ltd was established.
2016 The Company was incorporated in the Cayman Islands on June 30, 2016 as an exempted company with limited liability under the Companies Act of the Cayman Islands.
In July 2016, the Company established I-Mab Biopharma Hong Kong Limited, or I-Mab Hong Kong, as its intermediary holding company. In August 2016, I-Mab Hong Kong established a wholly-owned PRC subsidiary, I-Mab Biopharma Co., Ltd., or I-Mab Shanghai. In September 2016, the assets and operations of Third Venture Biopharma (Nanjing) Co., Ltd were consolidated into I-Mab Shanghai.
2020 On January 17, 2020, its ADSs commenced trading on the Nasdaq Global Market under the symbol “IMAB.”
2023 In October 2023, the Company divested the 51 equity interest in Zhejiang Tianli Pharmaceutical Sales Co., Ltd. previously held by I-Mab Biopharma Co., Ltd.